Business
Detailed Results From B-Series OCT with ImgAssist AI 2.0 Pivotal Trial Presented at ASBrS 2025
Detailed Results From B-Series OCT with ImgAssist AI 2.0 Pivotal Trial Presented at ASBrS 2025 ...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n\n\n\n Detailed Results From B-Series OCT with ImgAssist AI 2.0 Pivotal Trial Presented at ASBrS 2025\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n\n\n\n\n\n – First-ever successful pivotal trial of a new intraoperative margin assessment technology in breast cancer –\n \n\n\n\n – Pivotal trial met its primary endpoint with statistically significant reduction in patients with residual cancer during surgery (p-value = 0.0050) and demonstrated super-superiority compared to standard-of-care alone–\n \n\n\n\n – ASBrS presentation highlighted both these previously reported positive topline results and new additional analyses, including secondary endpoints and additional reporting –\n \n\n\n\n\n TORONTO\n \n and\n \n DALLAS\n \n\n ,\n \n\n May 5, 2025\n \n\n /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (\"Perimeter\" or the \"Company\"), a commercial-stage medical technology company, is pleased to announce detailed results from the pivotal trial evaluating the use of its next-generation B-Series OCT with ImgAssist AI 2.0 (\"Perimeter B-Series\" or \"OCT-AI\") for intraoperative margin assessment during breast-conserving surgeries (\"BCS\").\n \n\n The positive pivotal trial results were presented this past Saturday during the scientific session of the\n \n 26\n \n th\n \n Annual Meeting of the American Society of Breast Surgeons\n \n (\"ASBrS\") by Dr.\n \n Alastair Thompson\n \n , the trial's Primary Principal Investigator, Surgeon and Professor, Section Chief of Breast Surgery, Olga Keith Wiess Chair of Surgery at\n \n Baylor College of Medicine\n \n , Breast Cancer Program Leader at the Dan L Duncan Comprehensive Cancer Center.\n \n\n Dr. Thompson commented, \"Today, intraoperative margin assessment remains one of the most pressing problems for both surgeons and their patients. The final results of this pivotal trial clearly demonstrate that the use of Perimeter B-Series has the potential to change the current paradigm...